Lingling du, MD
Hematology & Oncology · New Orleans, LANPI 1003103532
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $125,229 of the $172,848 with a category attached, or 72.5%. 23 manufacturers reported payments, led by Boston Scientific at 52.2% of the total. 2025 is the largest year on record at $78,769, 7.6 times the $10,334 reported in 2022. Among hematology & oncology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 260 payments — averaging $664.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$90K
- Exelixis Inc.$41K
- Ipsen Biopharmaceuticals, Inc$21K
- AstraZeneca$7K
- Sirtex Medical Inc$5K
- E.r. Squibb & Sons, L.L.C.$3K
- plus $7K from 17 others
Across 184 payments — averaging $5541.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$411K
- Boston Scientific$408K
- Genentech, Inc.$69K
- Novartis$52K
- AstraZeneca$30K
- Janssen Research & Development, LLC$25K
- plus $26K from 2 others
What the payments were for
- Consulting fees$19,34411%
- Speaking & faculty fees$125,22972%
- Travel & lodging$22,03913%
- Food & beverage$6,1024%
- Education$1340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 106 | $90,170 |
| Exelixis Inc. | 80 | $40,789 |
| Ipsen Biopharmaceuticals, Inc | 15 | $20,614 |
| AstraZeneca | 9 | $6,862 |
| Sirtex Medical Inc | 7 | $4,548 |
| E.r. Squibb & Sons, L.L.C. | 7 | $2,602 |
| Beone Medicines USA, Inc. | 4 | $2,008 |
| Array Biopharma Inc | 2 | $1,890 |
| Incyte Corporation | 2 | $1,226 |
| Eisai Inc. | 2 | $867 |
| Genentech USA, Inc. | 4 | $273 |
| Novartis | 7 | $265 |
| Intera Oncology, Inc | 1 | $202 |
| Trisalus Life Sciences, Inc. | 1 | $160 |
| Tersera Therapeutics LLC | 3 | $83 |
| GSK | 1 | $57 |
| Astellas Pharma US Inc | 3 | $57 |
| Johnson & Johnson | 1 | $48 |
| Masimo Corporation | 1 | $39 |
| Daiichi Sankyo Inc. | 1 | $26 |
| AbbVie | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Beigene USA, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TheraSphere Y90 Glass Microspheres 10 GBq$62,843
- Cabometyx$35,398
- ONIVYDE$20,332
- TheraSphere Y90 Glass Microspheres 7.0 GBq (US Commercial)$16,489
- General - Interventional Oncology$6,688
- SIR-Spheres Microspheres$4,514
- IMFINZI$2,775
- BRAFTOVI$1,890
- Enhertu$1,388
- ZYNYZ$1,100
- LENVIMA$790
- INTERA$202
- TRINAV INFUSION SYSTEM$160
- PEMAZYRE$126
- TECENTRIQ$111
- SOMATULINE DEPOT$100
How this compares
$172,848 in reported general payments places this provider in the 95th percentile of 183 hematology & oncology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 13 | $375,523 |
| XermeloTelotristat Etiprate | 22 | $190,665 |
| NubeqaDarolutamide | 12 | $163,216 |
| CreonLipase/Protease/Amylase | 30 | $43,367 |
| EliquisApixaban | 45 | $39,707 |
| Everolimus | 14 | $23,661 |
| Enoxaparin Sodium | 27 | $10,531 |
| Ondansetron OdtOndansetron | 75 | $1,245 |
| Letrozole | 43 | $1,174 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 26 | $933 |
| Oxycodone Hcl | 51 | $891 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 45 | $751 |
| Cyproheptadine Hcl | 36 | $693 |
| Dexamethasone | 16 | $493 |
| SpsSodium Polystyrene Sulfon/Sorb | 20 | $469 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Exelixis Inc.Cabometyx | $40,789 | $375,52313 claims |
| Tersera Therapeutics LLCXermelo | $83 | $190,66522 claims |
| AbbVieCreon | $21 | $43,36730 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 183 hematology & oncology providers in Louisiana.
Other hematology & oncology in New Orleans
- Pedro BarataNew Orleans$928K
- Maissaa JanbainNew Orleans$862K
- Marc MatranaNew Orleans$757K
- Cindy LeissingerNew Orleans$135K
- Carter DavisNew Orleans$61K
- Furhan YunusNew Orleans$55K
- Michelle LochNew Orleans$50K
- David MorrisonNew Orleans$23K
- Scott SonnierNew Orleans$20K
- Ralph MillettNew Orleans$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.